Meeting
2018 ASCO Annual Meeting
ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.
Authors
Anna F. Farago
Massachusetts General Hospital, Boston, MA
Anna F. Farago , Luis G. Paz-Ares , Tudor-Eliade Ciuleanu , Andrea Fülop , Alejandro Navarro , Laura Bonanno , Jose Antonio Lopez-Vilariño , Rafael Nuñez , Carmen Maria Kahatt , Gabor Kos , Arturo Soto-Matos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02566993
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS8587)
DOI
10.1200/JCO.2018.36.15_suppl.TPS8587
Abstract #
TPS8587
Poster Bd #
189b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.
First Author: Alejandro Navarro
Poster
2023 ASCO Annual Meeting
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
First Author: Sophie Cousin
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2020 ASCO Virtual Scientific Program
Pooled safety analysis of single-agent lurbinectedin versus topotecan (Results from a randomized phase III trial CORAIL and a phase II basket trial).
First Author: Alexandra Leary